Care Oncology is pleased to announce the publication of its preliminary results in treating patients suffering from glioblastoma. Using a combination of medicines which are thought to collectively target cancer metabolism, the Care Oncology protocol is used as an adjunctive treatment alongside patients’ standard of care (SoC) cancer therapies. The treatment was administered by experienced doctors with specific training in the use of these medicines in an oncology setting concurrent with the SoC that patients were receiving at any point in time.
The data was analyzed by an independent auditing company (Cytel Inc.).
The open-access publication in Frontiers in Pharmacology can be found here.